Related Experiment Video
Updated: Aug 9, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed
Laurel W Rice1, Rebecca L Stone, Miaohou Xu
1Norman Thornton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 22908, USA. lwr9y@virginia.edu
Objective:
The purpose of this study was to investigate the AKT signaling cascade in endometrial cancers and to assess its therapeutic potential.
Study Design:
Western blotting and immunohistochemistry were used to investigate the expression of estrogen receptor, progesterone receptor, HER2, AKT, and 4EBP1 proteins in 27 atrophic endometria, 31 grade 1 and 24 grade 3 endometrioid endometrial cancers, and 19 malignant mixed müllerian tumors. Inhibition of the AKT signaling cascade was investigated in cell lines.
Results:
Malignant mixed müllerian tumors and grade 3 endometrioid endometrial cancers demonstrated higher levels of AKT and 4EBP1 activation and hormone receptor loss compared with grade 1 endometrioid endometrial cancers and atrophic samples. HER2 over-expression was identified most often in grade 3 tumors without gene amplification. In endometrial cancer cell-lines, AKT cascade inhibitors decreased cell proliferation by apoptosis and cell cycle arrest.
Conclusion:
AKT cascade activation in grade 3 endometrioid endometrial cancers and malignant mixed müllerian tumors is a novel finding. Apoptosis and growth arrest that results from AKT inhibition expose opportunities for therapeutic intervention.
Insights
AKT signaling cascade activation is elevated in aggressive endometrial cancers, suggesting new therapeutic targets. Inhibiting this pathway induces apoptosis and growth arrest, offering potential treatment strategies for advanced disease.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The AKT signaling pathway plays a crucial role in cell survival and proliferation.
- Dysregulation of AKT signaling is implicated in various cancers, including endometrial cancer.
- Understanding AKT activation in different endometrial cancer subtypes is essential for targeted therapy.
Purpose of the Study:
- To investigate the expression and activation of the AKT signaling cascade in endometrial cancers.
- To evaluate the therapeutic potential of targeting the AKT pathway in endometrial cancer.
Main Methods:
- Western blotting and immunohistochemistry were employed to analyze protein expression (ER, PR, HER2, AKT, 4EBP1).
- Samples included atrophic endometria, endometrioid endometrial cancers (grades 1-3), and malignant mixed müllerian tumors.
- In vitro studies utilized AKT cascade inhibitors in endometrial cancer cell lines.
Main Results:
- Higher AKT and 4EBP1 activation and hormone receptor loss were observed in high-grade endometrioid cancers and malignant mixed müllerian tumors compared to low-grade cancers.
- HER2 over-expression was frequent in grade 3 tumors, often without gene amplification.
- AKT cascade inhibitors reduced cell proliferation via apoptosis and cell cycle arrest in cell lines.
Conclusions:
- Elevated AKT cascade activation is a novel finding in aggressive endometrial cancers (grade 3 endometrioid and malignant mixed müllerian tumors).
- Targeting the AKT pathway effectively induces apoptosis and growth arrest.
- AKT pathway inhibition presents a promising therapeutic strategy for endometrial cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase